



AGENDA

Tuesday, June 20, 2017

| | |
|------------|--|
| 7:00 a.m. | BREAKFAST AVAILABLE |
| 7:30 a.m. | Welcome to Heart House <i>Kim Allan Williams, Sr., MD, MACC, FAHA, MASNC, FESC; ACC Past President</i> |
| 7:40 a.m. | Opening Remarks and Introductions <i>Mikhail Kosiborod, MD, FACC, FAHA and Laurence S. Sperling, MD, FACC; Co-Chairs</i> |
| 8:00 a.m. | SESSION 1: TRANSFORMING THE PARADIGM OF DIABETES MANAGEMENT FROM GLYCEMIC CONTROL TO COMPREHENSIVE CV DISEASE RISK REDUCTION <ul style="list-style-type: none">• Setting the Stage: The Coming Paradigm Shift in T2DM Management from HbA1c to CV Disease Risk Reduction <i>Mikhail Kosiborod, MD, FACC, FAHA (10 minutes)</i>• The Evolution of CV Outcomes Trials in T2DM Over the Years <i>Darren K. McGuire, MD, MHSc, FACC (10 minutes)</i>• Recent Breakthroughs in CV Outcomes Trials in T2DM <i>Benjamin M. Scirica, MD MPH, FACC (10 minutes)</i>• Interactive Table Discussion (60 minutes)• Report Back to Full Group (30 minutes) |
| 10:00 a.m. | BREAK |
| 10:15 a.m. | SESSION 2: DEFINING THE ROLE OF THE CV CLINICIAN IN COMANAGING CV RISK REDUCTION IN THE T2DM PATIENT POPULATION <ul style="list-style-type: none">• The Evolving Role of the CV Clinician in Managing CV Disease Risk in Patients with T2DM <i>Nathan D. Wong, PhD, FACC, FAHA (10 minutes)</i>• Utilizing Antidiabetic Agents to Reduce CV Disease Risk in Patients with T2DM <i>James LaSalle, DO, FAAFP (10 minutes)</i>• Barriers to Implementation of Preventive Therapies in CV Disease Risk Reduction in Patients with T2DM <i>Kim K. Birtcher, PharmD, MS, AACC, CDE (10 minutes)</i>• Interactive Table Discussion (60 minutes)• Report Back to Full Group (30 minutes) |
| 12:15 p.m. | LUNCH |
| 1:15 p.m. | SESSION 3: HARMONIZING CARE FOR CV DISEASE RISK REDUCTION IN PATIENTS WITH T2DM <ul style="list-style-type: none">• Adapting the “Heart Team” Approach for the Care of High-Risk Patients with T2DM <i>Robert H. Eckel, MD and Laurence S. Sperling, MD, FACC (10 minutes)</i>• Leveraging Registry Data: Uncovering Gaps and Discovering Opportunities to Improve How We Manage CV Disease Risk in Patients with T2DM <i>Suzanne V. Arnold, MD, MHA (10 minutes)</i>• Redefining Quality of Care in T2DM Patients with CV Disease <i>Melissa L. Magwire, RN, CDE (10 minutes)</i>• Interactive Table Discussion (60 minutes)• Report Back to Full Group (30 minutes) |
| 3:15 p.m. | Recap of the Day and Next Steps <i>Mikhail Kosiborod, MD, FACC, FAHA and Laurence S. Sperling, MD, FACC; Co-Chairs</i> |
| 4:00 p.m. | ADJOURN |